Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 31
Filtrar
3.
Eur Rev Med Pharmacol Sci ; 24(11): 5863-5870, 2020 06.
Artigo em Inglês | MEDLINE | ID: mdl-32572898

RESUMO

OBJECTIVE: We aimed at investigating the possible role and mechanism of NEAT1 in the pathogenesis of diabetic cataract. PATIENTS AND METHODS: YY1 and NEAT1 expressions in anterior lens capsule collected from diabetic cataract (DC) patients and normal controls were examined by quantitative real-time polymerase chain reaction (qRT-PCR) analysis, and their correlation was analyzed. The binding site between YY1 and NEAT1 sequences was predicted by JASPAR and detected by Dual-Luciferase reporter assay and chromatin immunoprecipitation (ChIP) assay. The proliferation and apoptosis of high-glucose-induced cells with NEAT1 knockdown were detected. Potential downstream targets of NEAT1 were predicted by bioinformatics and detected by Dual-Luciferase reporter assay. RESULTS: YY1 and NEAT1 expressions in the anterior capsule tissue of DC lens were remarkably reduced and positively correlated. Dual-Luciferase reporter assay and ChIP confirmed that YY1 could bind to locus 2 of NEAT1. Knockdown of NEAT1 inhibited proliferation while promoted apoptosis under high glucose conditions. Further mechanism studies revealed that knockdown of NEAT1 could upregulate microRNA-205-3p, and MMP16 was a potential target of miR-205. CONCLUSIONS: The low expression of YY1 induces NEAT1 downregulation, which regulates microRNA-205-3p/MMP16 axis and thus participates in the development of DC.


Assuntos
Catarata/metabolismo , Diabetes Mellitus Tipo 2/metabolismo , Metaloproteinase 16 da Matriz/metabolismo , MicroRNAs/metabolismo , RNA Longo não Codificante/metabolismo , Fator de Transcrição YY1/metabolismo , Apoptose , Catarata/patologia , Proliferação de Células , Diabetes Mellitus Tipo 2/patologia , Humanos , Metaloproteinase 16 da Matriz/genética , MicroRNAs/genética , RNA Longo não Codificante/genética , Células Tumorais Cultivadas , Fator de Transcrição YY1/genética
4.
Zhonghua Yi Xue Za Zhi ; 100(20): 1578-1581, 2020 May 26.
Artigo em Chinês | MEDLINE | ID: mdl-32450648

RESUMO

Objective: To clarify the clinical characteristics of chest infections caused by streptococcus anginosus group (SAG). Methods: A total of 26 patients diagnosed in Affiliated Hospital of Jining Medical University from January 2014 to October 2019 were enrolled. The analyzed clinical data included baseline data, clinical symptoms, imaging manifestations, therapies, and outcomes. The microbiological diagnosis was established based on the specimens collected by lung needle biopsy, bronchoscopy, artificial airway aspiration, thoracentesis or thoracoscopy. Results: Among the 26 patients, there were 23 (88.5%) males and 3 (11.5%) females aged (63.0±12.5) years, and 21 cases (80.8%) had potential diseases. The distribution of clinical manifestations included 21 cases (80.8%) with fever, 13 cases (50.0%) with pectoralgia, 13 cases (50.0%) with cough, and 13 cases (50.0%) with expectoration. Chest CT displayed 18 cases (69.2%) with nodules, 18 cases (69.2%) with pleural effusion, 17 cases (65.4%) with patchy shadows, 12 cases (46.2%) with consolidation, 4 cases (15.4%) with cavity, 3 cases (11.5%) with spontaneous pneumothorax. 13 cases (50.0%) of Streptococcus constellatus, 12 cases (46.2%) of Streptococcus anginosus and 1 case (3.8%) of Streptococcus intermadius were observed through the bacterial culture. After anti-infection treatment and invasive operation (including tracheoscopy, thoracoscopy, lung puncture, and thoracic puncture drainage), the prognosis of 24 cases (92.3%) became satisfactory, and 2 (7.7%) died. Conclusion: Pulmonary infection caused by SAG is mainly seen in male patients with underlying diseases. No specificity is displayed in clinical manifestations. CT manifestations usually show intrapulmonary nodules, patchy shadows, consolidation and pleural effusion.


Assuntos
Derrame Pleural , Infecções Respiratórias , Infecções Estreptocócicas , Idoso , Tosse , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Streptococcus anginosus
6.
Zhonghua Xue Ye Xue Za Zhi ; 39(7): 558-562, 2018 Jul 14.
Artigo em Chinês | MEDLINE | ID: mdl-30122014

RESUMO

Objective: To investigate the prognosis of allogeneic hematopoietic stem-cell transplantation (allo-HSCT) for patients with acute myeloid leukemia and MLL rearrangement. Methods: From September 2009 to May 2016, the clinical data of 47 patients with MLL-rearranged AML undergoing allo-HSCT in the First Affiliated Hospital of Soochow University were retrospectively analyzed. Results: Among 47 MLL-rearranged AML patients, 24 were male and 23 female. The median age was 30 (15-58) years old. There are 36 (76%) patients were FAB-types M4/M5. Two-year overall survival (OS), disease-free survival (DFS), relapse incidence and transplant-related mortality (TRM) were (64.4±8.4)%, (47.3±9.3)%, 41.0% and 17.9%, respectively. Of them, 45 patients were detected with 11q23 translocations, and 2 patients with normal karyotype were MLL partial tandem duplication. According to different chromosome karyotype, 47 patients were divided into three groups: 16 cases of t (6; 11), 15 cases of t (9; 11) and 16 cases of other types. Overall survival was compared between the three groups, there was no significant difference (χ(2)=1.509, P=0.472). On multivariate analysis, independent risk factor on OS was transplant age >45 years [HR=4.454(95%CI 1.314-15.099), P=0.016]. The multivariate analysis also confirmed the higher TRM in patients at non-CR state when transplanted [HR=10.370(95%CI 1.043-103.110), P=0.046]. Positive minimal residual disease (MRD) before transplantation was a negative prognostic factor on DFS [HR=4.236(95%CI 1.238-14.495), P=0.021] and relapse incidence (RI) [HR=5.491(95%CI 1.371-21.995), P=0.016]. Conclusion: Transplant age (>45 years), allo-HSCT in non-CR state adn positive MRD before transplantation were negative prognostic factors in allo-HSCT for MLL-rearranged AML patients.


Assuntos
Leucemia Mieloide Aguda , Adolescente , Adulto , Feminino , Transplante de Células-Tronco Hematopoéticas , Histona-Lisina N-Metiltransferase , Humanos , Leucemia Mieloide Aguda/terapia , Masculino , Pessoa de Meia-Idade , Proteína de Leucina Linfoide-Mieloide , Prognóstico , Estudos Retrospectivos , Transplante Homólogo , Adulto Jovem
7.
Zhonghua Xue Ye Xue Za Zhi ; 39(12): 983-988, 2018 Dec 14.
Artigo em Chinês | MEDLINE | ID: mdl-30612398

RESUMO

Objective: To investigate the survival and prognostic factors of allogeneic hematopoietic stem-cell transplantation (allo-HSCT) for patients with myeloid neoplasms and RUNX1 mutations. Methods: From July 2014 to April 2018, the clinical data of forty-two AML/MDS patients with RUNX1 mutations in the First Affiliated Hospital of Soochow University were retrospectively analyzed. The clinical characteristic features and distribution of the mutations frequently observed with RUNX1 mutations were summarized, the prognosis of allo-HSCT for these patients was also analyzed. Results: Among 42 AML/MDS patients with RUNX1 mutations, 27 were male, 15 were female. The median age was 43.5 (16-68) years old. There are 31 patients in allo-HSCT group and 11 patients in chemotherapy group. RUNX1 mutations co-occurred with many other gene mutations, the most frequent mutations were FLT3 (26.2%, 11/42) . Interestingly, FLT3 mutations only occurred in AML patients compared with MDS patients (P=0.014) . ASXL1 (25%, 3/12) mutations were observed as the most frequent co-mutations in MDS patients. One-year overall survival (OS) , disease-free survival (DFS) of allo-HSCT and chemotherapy patients were (70.6±9.0) %, (61.0±9.4) % and (34.4±16.7) %, (22.4±15.3) %, respectively. When OS and DFS between allo-HSCT and chemotherapy patients were compared, significant differences (χ(2)=4.843, 4.320, P<0.05) were showed. In univariate analysis, transplant age >45 years was a negative effect for OS [HR=4.819 (95% CI 1.145-20.283) , P=0.032] and DFS [HR=5.945 (95% CI 1.715-20.604) , P=0.005]. Also, complex chromosome karyotype abnormality was a negative effect for OS [HR=5.572 (95%CI 1.104-28.113) , P=0.038]. Conclusion: Transplant age (>45 years) and complex chromosome karyotype abnormality were negative prognostic factors in allo-HSCT for myeloid neoplasms patients with RUNX1 mutations.


Assuntos
Subunidade alfa 2 de Fator de Ligação ao Core/genética , Leucemia Mieloide Aguda/genética , Mutação , Adulto , Idoso , Feminino , Transplante de Células-Tronco Hematopoéticas , Humanos , Masculino , Pessoa de Meia-Idade , Prognóstico , Estudos Retrospectivos , Transplante Homólogo
8.
Oncogene ; 37(8): 1049-1061, 2018 02 22.
Artigo em Inglês | MEDLINE | ID: mdl-29084211

RESUMO

Metastasis significantly reduces the survival rate of osteosarcoma (OS) patients. Therefore, identification of novel targets remains extremely important to prevent metastasis and treat OS. In this report, we show that SPARCL1 is downregulated in OS by epigenetic methylation of promoter DNA. In vitro and in vivo experiments revealed that SPARCL1 inhibits OS metastasis. We further demonstrated that SPARCL1-activated WNT/ß-catenin signaling by physical interaction with various frizzled receptors and lipoprotein receptor-related protein 5/6, leading to WNT-receptor complex stabilization. Activation of WNT/ß-catenin signaling contributes to the SPARCL1-mediated inhibitory effects on OS metastasis. Furthermore, we uncovered a paracrine effect of SPARCL1 on macrophage recruitment through activated WNT/ß-catenin signaling-mediated secretion of chemokine ligand5 from OS cells. These findings suggest that the targeting of SPARCL1 as a new anti-metastatic strategy for OS patients.


Assuntos
Proteínas de Ligação ao Cálcio/metabolismo , Proteínas da Matriz Extracelular/metabolismo , Regulação Neoplásica da Expressão Gênica , Neoplasias Pulmonares/secundário , Macrófagos/metabolismo , Osteossarcoma/patologia , Proteínas Wnt/metabolismo , beta Catenina/metabolismo , Animais , Apoptose , Biomarcadores Tumorais/genética , Biomarcadores Tumorais/metabolismo , Neoplasias Ósseas/genética , Neoplasias Ósseas/metabolismo , Neoplasias Ósseas/patologia , Proteínas de Ligação ao Cálcio/genética , Movimento Celular , Proliferação de Células , Quimiocina CCL5/genética , Quimiocina CCL5/metabolismo , Proteínas da Matriz Extracelular/genética , Receptores Frizzled/genética , Receptores Frizzled/metabolismo , Humanos , Proteína-5 Relacionada a Receptor de Lipoproteína de Baixa Densidade/genética , Proteína-5 Relacionada a Receptor de Lipoproteína de Baixa Densidade/metabolismo , Proteína-6 Relacionada a Receptor de Lipoproteína de Baixa Densidade/genética , Proteína-6 Relacionada a Receptor de Lipoproteína de Baixa Densidade/metabolismo , Neoplasias Pulmonares/genética , Neoplasias Pulmonares/metabolismo , Macrófagos/patologia , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Nus , Invasividade Neoplásica , Osteossarcoma/genética , Osteossarcoma/metabolismo , Células Tumorais Cultivadas , Proteínas Wnt/genética , Ensaios Antitumorais Modelo de Xenoenxerto , beta Catenina/genética
10.
12.
Cell Death Dis ; 7: e2089, 2016 Feb 11.
Artigo em Inglês | MEDLINE | ID: mdl-26866270

RESUMO

The pseudokinase mixed lineage kinase domain-like protein (MLKL) is a key component of tumor necrosis factor (TNF)-induced necroptosis and plays a crucial role in necroptosis execution. However, the mechanisms that control MLKL activity are not completely understood. Here, we identify the molecular chaperone Hsp90 as a novel MLKL-interacting protein. We show that Hsp90 associates with MLKL and is required for MLKL stability. Moreover, we find that Hsp90 also regulates the stability of the upstream RIP3 kinase. Interference with Hsp90 function with the 17AAG inhibitor destabilizes MLKL and RIP3, resulting in their degradation by the proteasome pathway. Furthermore, we find that Hsp90 is required for TNF-stimulated necrosome assembly. Disruption of Hsp90 function prevents necrosome formation and strongly reduces MLKL phosphorylation and inhibits TNF-induced necroptosis. Consistent with a positive role of Hsp90 in necroptosis, coexpression of Hsp90 increases MLKL oligomerization and plasma membrane translocation and enhances MLKL-mediated necroptosis. Our findings demonstrate that an efficient necrotic response requires a functional Hsp90.


Assuntos
Proteínas de Choque Térmico HSP90/metabolismo , Proteínas Quinases/metabolismo , Fator de Necrose Tumoral alfa/metabolismo , Apoptose/fisiologia , Estabilidade Enzimática , Células HEK293 , Proteínas de Choque Térmico HSP90/genética , Humanos , Necrose/metabolismo , Necrose/patologia , Fosforilação , Transdução de Sinais , Transfecção , Fator de Necrose Tumoral alfa/genética
14.
J Int Med Res ; 39(5): 1961-7, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-22118000

RESUMO

Hepcidin plays a key role in iron homeostasis. This cross-sectional study measured the serum hepcidin levels of 48 maintenance haemodialysis patients and 20 age-matched healthy control subjects using a competitive enzyme-linked immunosorbent assay (C-ELISA). Serum hepcidin, interleukin (IL)-6 and high-sensitivity C-reactive protein levels were significantly higher in maintenance haemodialysis patients compared with control subjects. In all patients, there was a positive correlation between serum hepcidin levels and ferritin, transferrin saturation and IL-6, and an inverse correlation between serum hepcidin and unsaturated iron-binding capacity, total iron-binding capacity (TIBC) and transferrin. Linear regression analyses showed that ferritin and TIBC were independently associated with serum hepcidin levels. In conclusion, serum hepcidin levels are associated with iron status and microinflammation (defined as hsCRP < 15 mg/l, without clinical manifestation of inflammation) in maintenance haemodialysis patients. The C-ELISA method for measuring serum hepcidin should facilitate the routine measurement of hepcidin in clinical practice.


Assuntos
Peptídeos Catiônicos Antimicrobianos/sangue , Ferro/metabolismo , Diálise Renal , Adulto , Idoso , Biomarcadores/sangue , Proteína C-Reativa/metabolismo , Estudos de Casos e Controles , Estudos Transversais , Ensaio de Imunoadsorção Enzimática , Feminino , Ferritinas/metabolismo , Hepcidinas , Humanos , Inflamação/sangue , Interleucina-6/sangue , Falência Renal Crônica/sangue , Falência Renal Crônica/terapia , Masculino , Pessoa de Meia-Idade , Transferrina/metabolismo
15.
Clin Nephrol ; 76(6): 464-9, 2011 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-22105449

RESUMO

AIM: It has been recommended that patients should be admitted for 24 h of observation after percutaneous renal biopsy. This may be performed in the ambulatory outpatient setting, though its safety in this setting is an area of debate. We aim to demonstrate the safety of biopsy in the ambulatory outpatient setting. METHODS: We performed a retrospective cohort study of 475 biopsies performed in the ambulatory outpatient setting to examine safety and risk factors for complications. Transplant and native kidney biopsies performed at the Canberra Hospital, a tertiary referral university hospital, from 2006 until 2010 were included. Patients were observed for 6 h before discharge. Study outcomes were minor complications, defined as pain, hemorrhage or postural hypotension; or major complications, defined as complications requiring therapeutic intervention including blood product transfusion. RESULTS: The overall complication rate was 8.2%. There were 33 minor complications (6.9%) and 6 major complications (1.3%). All complications occurring outside the period of observation were safely managed. Significant predictors of any complication was hemoglobin (OR 1.03, 95% CI 1.01 - 1.06), kidney size (OR 0.93, 95% CI 0.89 - 0.98), and proceduralist. CONCLUSIONS: Percutaneous renal biopsy is safe in the ambulatory outpatient setting. Establishing ongoing quality assurance programs may be helpful in early identification of operator-dependent factors.


Assuntos
Biópsia/efeitos adversos , Rim/patologia , Adulto , Idoso , Feminino , Hemoglobinas/análise , Humanos , Masculino , Tamanho do Órgão , Pacientes Ambulatoriais , Segurança do Paciente , Estudos Retrospectivos
16.
J Int Med Res ; 39(2): 647-53, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-21672370

RESUMO

Early detection and timely intervention are important for improving contrast-induced nephropathy (CIN) prognosis. Whether urinary N-acetyl-ß-glucosaminidase (NAG) is a useful marker for early detection of CIN was investigated in 590 patients undergoing diagnostic coronary angiography (CA) and/or therapeutic percutaneous coronary intervention (PCI) for acute coronary syndromes or stable angina, and who received low-osmolality nonionic contrast agent. Urinary NAG, osmolality and serum creatinine were measured before and 1, 2 and 6 days after contrast agent exposure. CIN occurred in 33 patients; its incidence in high-risk patients (pre-existing renal dysfunction with/without diabetes mellitus) was significantly higher than in others. In patients with CIN, urinary NAG and serum creatinine levels on days 1 and 2 were significantly higher than at baseline and compared with patients without CIN; mean levels were gradually returning to baseline by day 6. Compared with serum creatinine, urinary NAG levels peaked earlier in CIN patients and increased much more. The results suggest that, following CA and/or PCI, CIN occurs to a certain degree and that NAG may be a useful early CIN marker as it is noninvasive, simple, inexpensive and sensitive.


Assuntos
Acetilglucosaminidase/urina , Meios de Contraste/efeitos adversos , Nefropatias/induzido quimicamente , Nefropatias/enzimologia , Angioplastia Coronária com Balão/efeitos adversos , Biomarcadores/urina , China/epidemiologia , Angiografia Coronária/efeitos adversos , Creatinina/sangue , Diabetes Mellitus/epidemiologia , Feminino , Humanos , Incidência , Nefropatias/sangue , Nefropatias/urina , Testes de Função Renal , Masculino , Pessoa de Meia-Idade , Concentração Osmolar
17.
Appl Radiat Isot ; 69(12): 1850-3, 2011 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-21530281

RESUMO

This paper aims to evaluate the effective dose as well as equivalent doses of several organs of an adult hermaphrodite mathematical phantom according to the definition of ICRP Publication 60 for BNCT treatments of brain tumors in the epithermal neutron beam at THOR. The MCNP5 Monte Carlo code was used for the calculation of the average absorbed dose of each organ. The effective doses for a typical brain tumor treatment with a tumor treatment dose of 20 Gy-eq were evaluated to be 0.59 and 0.35 Sv for the LLAT and TOP irradiation geometries, respectively. In addition to the stochastic effect, it was found that it is also likely to produce deterministic effects, such as cataracts and depression of haematopoiesis.


Assuntos
Terapia por Captura de Nêutron de Boro , Neoplasias Encefálicas/radioterapia , Humanos , Método de Monte Carlo
18.
Appl Radiat Isot ; 69(12): 1803-6, 2011 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-21478023

RESUMO

To introduce our preliminary experience of treating locally and regionally recurrent Head and Neck cancer patients at Tsing Hua Open-Pool Reactor in Taiwan, four patients (M/F=3/1, median age 68 Y/O) were enrolled. BNCT with BPA (400 mg/kg) injected in 2 phases and prescription dose of 12-35 Gy (Eq.)/fraction for 2 fractions at 30 day interval can be given with sustained blood boron concentration and tolerable early toxicities for recurrent H & N cancer.


Assuntos
Terapia por Captura de Nêutron de Boro , Carcinoma de Células Escamosas/radioterapia , Neoplasias de Cabeça e Pescoço/radioterapia , Idoso , Terapia por Captura de Nêutron de Boro/efeitos adversos , Feminino , Humanos , Masculino , Imagem Multimodal , Recidiva Local de Neoplasia , Tomografia por Emissão de Pósitrons , Taiwan , Tomografia Computadorizada por Raios X
19.
Appl Radiat Isot ; 67(7-8 Suppl): S247-50, 2009 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-19394237

RESUMO

In this article, we will consider several core configurations and run the core calculation with MCNP to obtain the neutrons distribution at THOR. The thermal neutron flux inside the vertical tubes (VT-B-VT-E) and the fast neutron flux in the first row facing to the boron neutron capture therapy (BNCT) facility (I3-I5) were tallied for indication. Based on these simulation results, the fuel elements were rearranged during the annual repair period in 2007. The epithermal neutron flux at the center of BNCT beam exit in air was measured again, and the results showed that the beam intensity increased by 50%. Comparing the neutron intensities both in reactor core and at the BNCT beam exit for several core configurations, the results show that the BNCT beam intensity can be increased without decreasing the neutron intensity in core.


Assuntos
Terapia por Captura de Nêutron de Boro/instrumentação , Reatores Nucleares , Fenômenos Biofísicos , Terapia por Captura de Nêutron de Boro/estatística & dados numéricos , Transferência de Energia , Arquitetura de Instituições de Saúde , Nêutrons Rápidos/uso terapêutico , Humanos , Modelos Estatísticos , Método de Monte Carlo , Taiwan
20.
Radiat Prot Dosimetry ; 113(2): 140-51, 2005.
Artigo em Inglês | MEDLINE | ID: mdl-15671054

RESUMO

Full-scale Monte Carlo simulations of the cyclotron room of the Buddhist Tzu Chi General Hospital were carried out to improve the original inadequate maze design. Variance reduction techniques are indispensable in this study to facilitate the simulations for testing a variety of configurations of shielding modification. The TORT/MCNP manual coupling approach based on the Consistent Adjoint Driven Importance Sampling (CADIS) methodology has been used throughout this study. The CADIS utilises the source and transport biasing in a consistent manner. With this method, the computational efficiency was increased significantly by more than two orders of magnitude and the statistical convergence was also improved compared to the unbiased Monte Carlo run. This paper describes the shielding problem encountered, the procedure for coupling the TORT and MCNP codes to accelerate the calculations and the calculation results for the original and improved shielding designs. In order to verify the calculation results and seek additional accelerations, sensitivity studies on the space-dependent and energy-dependent parameters were also conducted.


Assuntos
Ciclotrons , Arquitetura Hospitalar/métodos , Modelos Estatísticos , Monitoramento de Radiação/métodos , Proteção Radiológica/instrumentação , Proteção Radiológica/métodos , Medição de Risco/métodos , Algoritmos , Carga Corporal (Radioterapia) , Simulação por Computador , Desenho Assistido por Computador , Metodologias Computacionais , Arquitetura Hospitalar/instrumentação , Humanos , Método de Monte Carlo , Tomografia por Emissão de Pósitrons/instrumentação , Garantia da Qualidade dos Cuidados de Saúde/métodos , Doses de Radiação , Lesões por Radiação/prevenção & controle , Eficiência Biológica Relativa , Fatores de Risco , Software , Taiwan
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA